Search

Displaying results 2851 - 2860 of 10000 in total
  1. Drug

    Terconazole

    go.drugbank.com/drugs/DB00251
    Approved

    [A178096] Terconazole was initially approved by the FDA in 1987. … [FDA label] This drug is available in cream and suppository forms and both have demonstrated high levels of safety, efficacy, and tolerability in clinical trials.

  2. Drug

    Proguanil

    go.drugbank.com/drugs/DB01131
    Approved

    It does this by inhibiting the enzyme, dihydrofolate reductase, which is involved in the reproduction of the parasite. … Proguanil is a prophylactic antimalarial drug, which works by stopping the malaria parasite, _Plasmodium falciparum_ and _Plasmodium vivax_, from reproducing once it is in the red blood cells.

    Mixtures: ATOVAQUONE E PROGUANILE SANDOZ, ATOVAQUONE E PROGUANILE MYLAN GENERICS
  3. Drug

    Parathyroid hormone

    go.drugbank.com/drugs/DB05829
    ApprovedInvestigational

    Preotact is used in the treatment of osteoporosis in postmenopausal women at high risk of osteoporotic fractures and is marketed in Europe by Nycomed. … Available as Preotact, it is an identical form of human recombinant hormome which produced as a fusion protein undergoeing post-translational processing involving the cleavage of the OmpA leader sequence

  4. Drug

    Tenecteplase

    go.drugbank.com/drugs/DB00031
    ApprovedInvestigational

    amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296-299 in

  5. Drug

    Tioguanine

    go.drugbank.com/drugs/DB00352
    ApprovedInvestigational

    An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.

  6. Drug

    Mavacamten

    go.drugbank.com/drugs/DB14921
    ApprovedInvestigational

    It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. … [A248440] Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication.[L44106,L47471]

  7. Drug

    Narsoplimab

    go.drugbank.com/drugs/DB16418
    ApprovedInvestigational

    [A241030] Evidence increasingly points to a role for the complement system in TMA. … [A241045, A241050] Approved by the FDA on December 24, 2025, narsoplimab-wuug is indicated for the treatment of hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA) in adults

    Synonyms: IMMUNOGLOBULIN G4-LAMBDA, ANTI-(HOMO SAPIENS MANNAN-BINDING LECTIN SERINE PROTEASE 2 (MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASE 2, EC=3.4.21.104) HUMAN MONOCLONAL ANTIBODY .GAMMA.4 HEAVY CHAIN
  8. Drug

    Tivozanib

    go.drugbank.com/drugs/DB11800
    ApprovedInvestigational

    Renal cell carcinoma (RCC) is responsible for 3% of cancer cases[A231314] and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74. … It was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524]

  9. Drug

    Lobeline

    go.drugbank.com/drugs/DB05137
    Investigational

    An alkaloid that has actions similar to nicotine on nicotinic cholinergic receptors but is less potent. … It has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, and smoking cessation. [PubChem]

  10. Drug

    Somatrem

    go.drugbank.com/drugs/DB09098
    ApprovedWithdrawn

    continues to be mired in persistent bioethical debate [A32292]. … Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents